2289 — Charmacy Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapValue Trap

Annual income statement for Charmacy Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	CAS	CAS	CAS	CAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	3,794	4,175	4,404	4,435	4,385
Cost of Revenue
Gross Profit	229	262	283	314	330
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,761	4,054	4,337	4,362	4,317
Operating Profit	32.4	122	66.2	73.2	68.1
Other Net Non Operating Costs
Net Income Before Taxes	33	122	67.4	71.2	64.3
Provision for Income Taxes
Net Income After Taxes	23.2	90.5	51.3	53.3	46.3
Net Income Before Extraordinary Items
Net Income	23.2	90.5	51.3	53.3	46.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	23.2	90.5	51.3	53.3	46.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.234	0.407	0.506	0.518	0.455
Dividends per Share